MX2013012773A - Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. - Google Patents

Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.

Info

Publication number
MX2013012773A
MX2013012773A MX2013012773A MX2013012773A MX2013012773A MX 2013012773 A MX2013012773 A MX 2013012773A MX 2013012773 A MX2013012773 A MX 2013012773A MX 2013012773 A MX2013012773 A MX 2013012773A MX 2013012773 A MX2013012773 A MX 2013012773A
Authority
MX
Mexico
Prior art keywords
drug substances
preparing
methods
same
compositions
Prior art date
Application number
MX2013012773A
Other languages
English (en)
Inventor
Vincenzo Liotta
Dimitrios Zarkadas
Christopher Pridgen
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2013012773A publication Critical patent/MX2013012773A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se describen sustancias farmacológicas, que comprenden una forma amorfa sólida de un compuesto de fórmula estructural I y con un área superficial específica BET de hasta aproximadamente 94m2/g, composiciones farmacéuticas que comprenden dichas sustancias farmacológicas, procedimientos para la preparación de tales sustancias farmacológicas y usos de dichas sustancias farmacológicas y composiciones farmacéuticas. (Ver Formula).
MX2013012773A 2011-05-04 2012-05-02 Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. MX2013012773A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482592P 2011-05-04 2011-05-04
PCT/US2012/036131 WO2012151283A1 (en) 2011-05-04 2012-05-02 Drug substances, pharmeceutical compositions and methods for preparing the same

Publications (1)

Publication Number Publication Date
MX2013012773A true MX2013012773A (es) 2013-11-21

Family

ID=47108028

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013012773A MX2013012773A (es) 2011-05-04 2012-05-02 Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
MX2013012771A MX2013012771A (es) 2011-05-04 2012-05-02 Proceso para la preparacion de inhibidores del virus de la hepatitis c.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013012771A MX2013012771A (es) 2011-05-04 2012-05-02 Proceso para la preparacion de inhibidores del virus de la hepatitis c.

Country Status (17)

Country Link
US (2) US20140044759A1 (es)
EP (2) EP2704570A4 (es)
JP (2) JP2014515764A (es)
KR (2) KR20140030169A (es)
CN (2) CN103476260A (es)
AR (1) AR086259A1 (es)
AU (2) AU2012250799A1 (es)
BR (2) BR112013027652A2 (es)
CA (2) CA2832869A1 (es)
CO (1) CO6801768A2 (es)
IL (1) IL228601A0 (es)
MX (2) MX2013012773A (es)
RU (2) RU2013153533A (es)
SG (1) SG194711A1 (es)
TW (1) TW201247668A (es)
WO (2) WO2012151271A1 (es)
ZA (1) ZA201308011B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
CA2916143C (en) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
CA3055019A1 (en) * 2017-03-07 2018-09-13 Orion Corporation Manufacture of a crystalline pharmaceutical product
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
AR056805A1 (es) * 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
PL2121605T3 (pl) * 2006-12-20 2014-05-30 Merck Sharp & Dohme Sposób otrzymywania (1R,2S,5S)-N-[(1S)-3-amino-1-(cyklobutylo-metylo)-2,3-dioksypropylo]-3-[(2S)-2-[[[(1,1-dimetyloetylo)amino]-karbonylo]amino]-3,3-dimetylo-1-oksybutylo]-6,6-dimetylo-3-azabicyklo[3.1.0]heksano-2-karboksyamidu
MX2009008275A (es) * 2007-02-01 2009-08-12 Tibotec Pharm Ltd Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
JP4803074B2 (ja) * 2007-03-06 2011-10-26 日産化学工業株式会社 アルコール酸化触媒およびその合成方法
WO2009038663A1 (en) * 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
DE102009000662A1 (de) * 2009-02-06 2010-08-12 Evonik Degussa Gmbh Verfahren zur Herstellung von Aldehyden und Ketonen aus primären und sekundären Alkoholen

Also Published As

Publication number Publication date
KR20140022855A (ko) 2014-02-25
AR086259A1 (es) 2013-12-04
US20140058116A1 (en) 2014-02-27
TW201247668A (en) 2012-12-01
JP2014513127A (ja) 2014-05-29
EP2704576A4 (en) 2014-12-10
SG194711A1 (en) 2013-12-30
CO6801768A2 (es) 2013-11-29
AU2012250811A1 (en) 2013-12-19
CA2833887A1 (en) 2012-11-08
RU2013153588A (ru) 2015-06-10
CN103501608A (zh) 2014-01-08
BR112013027652A2 (pt) 2016-07-26
BR112013027642A2 (pt) 2016-07-26
IL228601A0 (en) 2013-12-31
JP2014515764A (ja) 2014-07-03
ZA201308011B (en) 2015-05-27
EP2704570A4 (en) 2015-02-18
CA2832869A1 (en) 2012-11-08
KR20140030169A (ko) 2014-03-11
RU2013153533A (ru) 2015-06-10
WO2012151283A1 (en) 2012-11-08
US20140044759A1 (en) 2014-02-13
EP2704570A1 (en) 2014-03-12
MX2013012771A (es) 2013-11-21
AU2012250799A1 (en) 2013-10-10
EP2704576A1 (en) 2014-03-12
NZ617300A (en) 2015-06-26
CN103476260A (zh) 2013-12-25
WO2012151271A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
IN2014MN02598A (es)
NZ729443A (en) Heterocyclic modulators of lipid synthesis
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
IN2014CN04530A (es)
IN2015DN01119A (es)
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2013004995A8 (en) Pyrimidinone compounds and their use
IL248510A0 (en) A process for preparing sustained release pharmaceutical preparations of somatostatin analogs
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EA029539B8 (ru) Фармацевтическая композиция ситаглиптина
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
AP2012006645A0 (en) Pharmaceutical compositions comprising paracetamoland process for preparing the same
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
MY181682A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
WO2013046233A3 (en) Process for the preparation of octreotide acetate